Difference between revisions of "Hals 2013 J Diabetes Res"
| Line 6: | Line 6: | ||
|abstract=Islet transplantation in diabetes is hampered by the need of life-long immunosuppression. Encapsulation provides partial immunoprotection but could possibly limit oxygen supply, a factor that may enhance hypoxia-induced beta cell death in the early post-transplantation period. Here we tested susceptibility of alginate microencapsulated human islets to experimental hypoxia (0.1-0.3 % O2 for 8 h, followed by re-oxygenation) on viability and functional parameters. Hypoxia reduced viability as measured by MTT by 33.8 ± 3.5 % in encapsulated and 42.9 ± 5.2 % in non-encapsulated islets (p < 0.2). Non-encapsulated islets released 37.7% (median) more HMGB1 compared to encapsulated islets after hypoxic culture conditions (p < 0.001). Glucose-induced insulin release was marginally affected by hypoxia. Basal oxygen consumption was equally reduced in encapsulated and non-encapsulated islets, by 22.0 ± 6.1 % vs. 24.8 ± 5.7 %. Among 27 tested cytokines/chemokines, hypoxia increased the secretion of IL-6 and IL-8/CXCL8 in both groups of islets whereas an increase of MCP-1/CCL2 was seen only with non-encapsulated islets. Conclusion: alginate microencapsulation of human islets does not increase susceptibility to acute hypoxia. This is a positive finding in relation to potential use of encapsulation for islet transplantation. | |abstract=Islet transplantation in diabetes is hampered by the need of life-long immunosuppression. Encapsulation provides partial immunoprotection but could possibly limit oxygen supply, a factor that may enhance hypoxia-induced beta cell death in the early post-transplantation period. Here we tested susceptibility of alginate microencapsulated human islets to experimental hypoxia (0.1-0.3 % O2 for 8 h, followed by re-oxygenation) on viability and functional parameters. Hypoxia reduced viability as measured by MTT by 33.8 ± 3.5 % in encapsulated and 42.9 ± 5.2 % in non-encapsulated islets (p < 0.2). Non-encapsulated islets released 37.7% (median) more HMGB1 compared to encapsulated islets after hypoxic culture conditions (p < 0.001). Glucose-induced insulin release was marginally affected by hypoxia. Basal oxygen consumption was equally reduced in encapsulated and non-encapsulated islets, by 22.0 ± 6.1 % vs. 24.8 ± 5.7 %. Among 27 tested cytokines/chemokines, hypoxia increased the secretion of IL-6 and IL-8/CXCL8 in both groups of islets whereas an increase of MCP-1/CCL2 was seen only with non-encapsulated islets. Conclusion: alginate microencapsulation of human islets does not increase susceptibility to acute hypoxia. This is a positive finding in relation to potential use of encapsulation for islet transplantation. | ||
|keywords=Human islets, microencapsulation, hypoxia, viability, oxygen consumption, insulin release, cytokine/chemokine secretion | |keywords=Human islets, microencapsulation, hypoxia, viability, oxygen consumption, insulin release, cytokine/chemokine secretion | ||
|mipnetlab=NO Trondheim Grill V | |||
}} | }} | ||
{{Labeling | {{Labeling | ||
Revision as of 08:42, 12 December 2013
| Hals IK, Rokstad AM, Strand BL, Oberholzer J, Grill V (2013) Alginate microencapsulation of human islets does not increase susceptibility to acute hypoxia. downloads.hindawi [epub ahead of print] |
Hals IK, Rokstad AM, Strand BL, Oberholzer J, Grill V (2013) downloads.hindawi
Abstract: Islet transplantation in diabetes is hampered by the need of life-long immunosuppression. Encapsulation provides partial immunoprotection but could possibly limit oxygen supply, a factor that may enhance hypoxia-induced beta cell death in the early post-transplantation period. Here we tested susceptibility of alginate microencapsulated human islets to experimental hypoxia (0.1-0.3 % O2 for 8 h, followed by re-oxygenation) on viability and functional parameters. Hypoxia reduced viability as measured by MTT by 33.8 ± 3.5 % in encapsulated and 42.9 ± 5.2 % in non-encapsulated islets (p < 0.2). Non-encapsulated islets released 37.7% (median) more HMGB1 compared to encapsulated islets after hypoxic culture conditions (p < 0.001). Glucose-induced insulin release was marginally affected by hypoxia. Basal oxygen consumption was equally reduced in encapsulated and non-encapsulated islets, by 22.0 ± 6.1 % vs. 24.8 ± 5.7 %. Among 27 tested cytokines/chemokines, hypoxia increased the secretion of IL-6 and IL-8/CXCL8 in both groups of islets whereas an increase of MCP-1/CCL2 was seen only with non-encapsulated islets. Conclusion: alginate microencapsulation of human islets does not increase susceptibility to acute hypoxia. This is a positive finding in relation to potential use of encapsulation for islet transplantation. • Keywords: Human islets, microencapsulation, hypoxia, viability, oxygen consumption, insulin release, cytokine/chemokine secretion
• O2k-Network Lab: NO Trondheim Grill V
Labels:
HRR: Oxygraph-2k
Labels [epub ahead of print]
